Medscape

FDA Backpedals on Warnings in Echo-Contrast Labeling

May 13, 2008 - The US FDA has approved less ominous and restrictive language for the labeling of the echocardiographic contrast agents perflutren lipid microspheres injectable suspension (Definity, ...
Medscape

FDA Puts Boxed Warning on Echo Contrast Agents

October 15, 2007 (Rockville, MD)-As expected, the US FDA has requested that a boxed warning be added to the labeling of two contrast agents used in echocardiography: perflutren liquid microspheres ...
Business Wire

Lantheus Medical Imaging Announces New National Contract with Novation for ABLAVAR ® and DEFINITY ®

Lantheus imaging products include the echocardiography contrast agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, ABLAVAR ® (gadofosveset trisodium), a first-in-class ...
Business Wire

Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY ® Room Temperature

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...
Healio

FDA approves cardiac ultrasound enhancing agent for pediatric patients

Please provide your email address to receive an email when new articles are posted on . The FDA approved perflutren lipid microsphere injection to improve ultrasound imaging in pediatric patients. The ...